ABSTRACT
BACKGROUND: Exacerbation of rosacea may occur during pregnancy and there are multiple associated cases of rosacea fulminans (RF). Treatment during pregnancy poses a significant challenge as many rosacea treatments are contraindicated or have limited evidence regarding potential adverse fetal effects. OBJECTIVE: Review the pregnancy categories of various treatments and develop algorithms for treating pregnant patients with rosacea and RF. METHODS: Rosacea treatments showing efficacy in randomized controlled trials were searched through DailyMed to review pregnancy labelling. Searching the PubMed/MEDLINE database for English articles using keywords "rosacea fulminans AND pregnancy" without publishing-time restrictions yielded 8 articles. We summarized treatments used in cases of RF during pregnancy. RESULTS: Topical ivermectin was more effective than metronidazole, but has a more concerning pregnancy category. Three pregnant women with RF were treated successfully with topical metronidazole in combination with other therapies. Azithromycin is the only oral rosacea therapy that is considered safe for pregnant patients and it has been used to treat RF. CONCLUSIONS: This review highlights the challenging aspects of treating pregnant patients with rosacea, as there is limited pregnancy-related treatment efficacy and safety data. The pregnancy categories of therapeutic options are summarized. Further studies are needed to learn which therapies are effective and safe for use during pregnancy.
Subject(s)
Algorithms , Pregnancy Complications/therapy , Rosacea/therapy , Adult , Animals , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use , Azithromycin/adverse effects , Azithromycin/therapeutic use , Brimonidine Tartrate/therapeutic use , Dermatologic Agents/therapeutic use , Dicarboxylic Acids/therapeutic use , Doxycycline/adverse effects , Doxycycline/therapeutic use , Female , Humans , Isotretinoin/adverse effects , Isotretinoin/therapeutic use , Ivermectin/adverse effects , Ivermectin/therapeutic use , Metronidazole/therapeutic use , Mice , Minocycline/adverse effects , Minocycline/therapeutic use , Phototherapy/adverse effects , Phototherapy/methods , Pregnancy , Randomized Controlled Trials as Topic , Tetracyclines/adverse effects , Tetracyclines/therapeutic use , Treatment OutcomeABSTRACT
Phototherapy is an effective treatment for multiple dermatoses. However, patient inconvenience and poor access to office-based phototherapy may jeopardize adherence and treatment outcome. Home phototherapy offers a convenient, accessible, and effective therapy. We describe the history of home phototherapy, the devices available, and associated costs. A literature review used PubMed. Keywords included: "home phototherapy," "tanning beds," "narrowband ultraviolet B." In a randomized control trial, home phototherapy had similar efficacy to office-based phototherapy. Home phototherapy is associated with significant cost savings treatment and increased adherence. Home phototherapy should be considered for its economic value, good tolerability, adherence, and efficacy.
Subject(s)
Home Care Services/organization & administration , Phototherapy/methods , Skin Diseases/therapy , HumansABSTRACT
BACKGROUND: Childhood atopic dermatitis is a chronic inflammatory skin condition that causes significant psychological and financial costs to the individual and society. Treatment regimens may require long-term medication adherence and can be associated with poor patient satisfaction. There is considerable interest in complementary and integrative medicine (CIM) approaches for childhood atopic dermatitis. OBJECTIVE: To assess the effects of CIM approaches on childhood atopic dermatitis outcomes as defined by randomized, controlled clinical trials. METHODS: A PubMed review of CIM-related treatments for pediatric atopic dermatitis was performed, and data related to age, study population, efficacy, treatment regimen, length of treatment, and sample size were included. RESULTS: The search yielded 20 trials related to probiotic/prebiotic treatments for atopic dermatitis, three on the effects of vitamins on children with atopic dermatitis, and two on the effects of Chinese herbal treatments for atopic dermatitis in children and adolescents. The strongest evidence was for supplementation with the probiotics L. fermentum and L. plantarum. CONCLUSIONS: Certain strains of probiotics, specifically L. plantarum and L. fermentum, may improve clinical severity scores in children with atopic dermatitis. However, additional trials are needed to more thoroughly delineate the effects of additional integrative therapies on childhood atopic dermatitis.
ABSTRACT
Although phototherapy is an effective treatment for many dermatological conditions on the face, trunk, and proximal extremities, a common issue plaguing whole-body phototherapy is its diminished efficacy on the legs. In this commentary, we elaborate on the factors underlying this phenomenon, as well as potential solutions to improve treatment success.
Subject(s)
Facial Dermatoses/radiotherapy , Leg Dermatoses/radiotherapy , Ultraviolet Therapy/methods , Whole-Body Irradiation/methods , Arm , Humans , Skin Diseases/radiotherapy , Torso , Treatment OutcomeABSTRACT
The original article was published on February 15, 2019 and corrected on April 15, 2019. The third pair of panes of Figure 2 were reversed, such that the pane previously depicted on the left was after phototherapy. The corrected sequence is now before phototherapy, on the left, and after, on the right. This change appears in the revised online PDF copy of this article.
ABSTRACT
OBJECTIVE: To measure adherence using a novel home UVB phototherapy system designed to promote adherence. STUDY DESIGN: A retrospective, observational study conducted to evaluate patients' adherence to a prescribed three-times-per-week treatment protocol using a novel home phototherapy system with integrated features designed to improve adherence. METHODS: Data was collected from 18 psoriasis patients, 27 vitiligo patients, and three atopic dermatitis patients using a novel home phototherapy system under normal use conditions. Adherence was also calculated using two alternative methods to allow for comparison between published phototherapy adherence studies. RESULTS: The median patient adherence (N= 48) to treatment with the home phototherapy system was 80%. There were no significant differences in adherence between different ages, genders, or diseases (P>0.05). Early adherence (N=48) to the home phototherapy system was 90% and dichotomous adherence (N=32) was 71%. CONCLUSIONS: By implementing a smartphone application and web-based portal with the home phototherapy system, patients have multiple mechanisms in place to ensure adherence.
Subject(s)
Dermatitis, Atopic/radiotherapy , Patient Compliance/statistics & numerical data , Psoriasis/radiotherapy , Ultraviolet Therapy/methods , Vitiligo/radiotherapy , Adult , Female , Humans , Male , Middle Aged , Mobile Applications , Patient Portals , Phototherapy/methods , Retrospective Studies , Smartphone , Ultraviolet Therapy/instrumentationABSTRACT
BACKGROUND: Phototherapy is effective in treating psoriasis and other skin conditions. However, clinic-based phototherapy can be time-consuming, expensive, and inconvenient. Conventional home phototherapy addresses many hurdles, but has other limitations. OBJECTIVE: Assess the treatment efficacy, adherence, and satisfaction of a novel ultraviolet B home phototherapy system. METHODS: Eight patients with stable plaque psoriasis completed a multicenter, prospective, open label, interventional study using a home phototherapy device designed to improve treatment control and adherence. Matched control and study lesions were assessed on each subject. A dosing protocol based on American Academy of Dermatology guidelines for narrowband UVB phototherapy was managed by the phototherapy system. Responsiveness to the treatment was measured using the Psoriasis Severity Index (PSI) at 10 weeks versus control. Patient satisfaction was graded on a five-star Likert scale. RESULTS: At 10 weeks, all patients experienced improvement in the treated lesions, with a mean improvement of 57% in PSI (P<0.0001 compared to baseline and P<0.0002 compared to the control lesions). Patient treatment adherence was 96% and treatment satisfaction was 100% five-star rated. Control lesions did not significantly change in PSI over the 10-week period (P=0.1411). CONCLUSIONS: The home phototherapy system provided a safe and effective means to manage plaque psoriasis.
Subject(s)
Psoriasis/radiotherapy , Self Care , Ultraviolet Therapy/methods , Humans , Mobile Applications , Patient Compliance , Patient Satisfaction , Severity of Illness Index , Smartphone , Ultraviolet Therapy/adverse effects , Ultraviolet Therapy/instrumentationABSTRACT
To assess the possible clinical implication of Dragon's Blood in dermatology, a PubMed search was conducted using the keyword "Dragon's Blood," "Croton lechleri," and more. Dragon's Blood from C. lechleri is an Amazonian medicinal plant with a characteristic red sap. Its array of phytochemical action in preclinical studies include anti-inflammatory, antioxidant, antimicrobial, antifungal, and antineoplastic properties. Clinical studies reflect wound healing and antiviral properties. Although its popularity is rising in western medicine, C. lechleri offers limited use in dermatology and further investigation is necessary to gain further insight into its potential clinical implication.
Subject(s)
Plant Extracts/administration & dosage , Skin Diseases/drug therapy , Wound Healing/drug effects , Animals , Croton/chemistry , Dermatology/methods , Humans , Plant Extracts/pharmacology , Skin Diseases/pathologyABSTRACT
Psoriasis treatments range from topical treatments and phototherapy to oral systemic medications and injections. Despite good control of the disease when applying appropriate treatments (according to disease severity, insurance parameters, patient preference, and patients' ability to adhere), continued advancements will allow even better symptomatic control, reduced adverse effects, and patient satisfaction. This review aims to assess traditional and new psoriasis treatments and how to apply them in clinical practice. A literature review on psoriasis treatments and clinical applications was performed using PubMed. Mild-to-moderate psoriasis treatments include topicals, localized phototherapy, and newer therapies combining two types of topicals, phototherapy with topicals, and easy-to-use foam and spray vehicles. Moderate-to-severe psoriasis therapies include monotherapy or various combinations of generalized phototherapy, oral treatments, and biologic agents, with new oral and biologic agents on the horizon. Dermatologists and primary care providers share roles in screening for associated comorbidities (including cardiovascular disorders, chronic kidney disease, Crohn disease, dyslipidemia, diabetes mellitus/insulin resistance, depression, metabolic syndrome, obesity, and psoriatic arthritis), managing patients' treatments, and reevaluating treatment needs as new therapies are approved. Continued advancements in psoriasis treatment and improvement in coordinated care will allow better overall care of patients with psoriasis.
Subject(s)
Psoriasis/therapy , Acitretin/therapeutic use , Administration, Topical , Adrenal Cortex Hormones/therapeutic use , Cyclosporine/therapeutic use , Dermatologic Agents/therapeutic use , Humans , Interleukins/antagonists & inhibitors , Methotrexate/therapeutic use , PUVA Therapy/methods , Phototherapy/methods , Psoriasis/drug therapy , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Vitamin D/analogs & derivativesABSTRACT
Analgesic medications compounded for topical use are gaining popularity for the management of chronic pain. The advantages of topical pain medications include reduction of systemic adverse effects, improved patient acceptance, few drug interactions, ease of dose determination, avoidance of first-pass metabolism, and direct access to the target site. Compounded topical medications typically use a mixture of 3 or more single medications to achieve multiple complementary effects at lower doses of each individual medication. Herein, we review the mechanisms, adverse effects, and evidence for some of the most commonly used medications in topical compounds for pain management. Because more topical medications are used for chronic pain, dermatologists can expect an increase in irritant and allergic contact dermatitis related to these medications.
Subject(s)
Analgesics/administration & dosage , Chronic Pain/drug therapy , Administration, Cutaneous , Amines/administration & dosage , Amitriptyline/administration & dosage , Amitriptyline/analogs & derivatives , Anesthetics, Local/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Baclofen/administration & dosage , Capsaicin/administration & dosage , Clonidine/administration & dosage , Cyclohexanecarboxylic Acids/administration & dosage , Drug Combinations , Drug Compounding , Gabapentin , Humans , Ketamine/administration & dosage , Lidocaine/administration & dosage , Muscle Relaxants, Central/administration & dosage , gamma-Aminobutyric Acid/administration & dosageABSTRACT
INTRODUCTION: Biological agents have transformed psoriasis treatment by selectively targeting immune signaling molecules involved in psoriasis pathogenesis. While biologics offer the most effective treatment of moderate to severe psoriasis, they are not without complications. Some patients treated with biologics have poor clinical responses, form anti-drug antibodies, or develop adverse events. Additionally, there is growing need for head-to-head studies comparing biologic treatment regimens, efficacy, and safety. Areas covered: Here we review the literature surrounding biologics already in clinical use and those undergoing development and clinical trials. We also investigate the development and approval of small molecules inhibitors and biosimilars used to treat psoriasis. Expert commentary: As the psoriasis treatment armamentarium continues to expand, it is important to follow the safety profile of these drugs both in clinical trials and in post-marketing registries to ensure their long-term safety. Physicians must be aware of the limitations of existing safety data of a drug and the potential risk for rare adverse events when selecting appropriate treatments and monitoring patient outcomes.